BioStock: Strong start to 2022 for Respiratorius

2022 looks to be an eventful year for Lund-based Respiratorius, which released its report for the fourth quarter on Tuesday. The company has started the PK study with the new formulation of VAL001, while announcing a new capital injection and plans to spin off its respiratory project. BioStock contacted the company's CEO Johan Drott to dig a little deeper into the quarterly report and get his view on the interesting situation the company is in at the moment. 

Read the full interview with Johan Drott at biostock.se:

https://www.biostock.se/en/2022/02/strong-start-to-2022-for-respiratorius/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se